Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: Troll_29 who wrote (985)	4/18/1999 10:03:00 AM
From: LLCF	Respond to of 3202

<Why is the obvious (to us) potential of INCY not reflected in the price?> I disagree somewhat in that another possibility exists: Analysts just aren't watching many biotechs that closely... especially money losing! So when the price crashed you didn't have a stable of new analyists jumping on board, everyone that likes INCY is already long and have "buy" on it. Why don't more analysts follow INCY? They have no earnings for one... (or won't this year). This lack of following allows for much larger price swings... DAK

To: Troll_29 who wrote (985)	4/18/1999 1:16:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 3202

I suspect that you're Trolling for answers from the thread in general, but I'm certainly not the person to be giving answers here. I just hang out and try to learn from other thread participants. Question..... didn't someone recently license the Southern patent and make a big deal out of such? I just searched the INCY 10-K for "Southern" and turned up nada. Is this important, from a positioning stand? Can someone add light? Thanks.